Friday, 23 Mar 2018

You are here

20% Price Hike Among Pfizer Drugs

The increasing cost of drug has been the subject of concern and review - by legislators, reporters and patients.

The Financial Times has reviewed the annual price increases for the 91 drugs in Pfizers portfolio, showing an average price increase by 20 percent in the past year.

This includes Viagra and Lyrica.

Drug pricing has become a highly publicized and contentious issue. Many manufacturers are pledging to be more transparent to address the concerns of payers, patients and politicians.

Price hikes are common.  The cost of three top-selling TNF inhibitors has risen from $18,000 per year in 2000 to nearly $48,000 per year in 2017.

Companies like Sanofi, AbbVie, Allergan and Novo Nordisk have announced their price increases would be in the single-digit percentage range this year.

The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Shoe Inserts Disappoint with Plantar Heel Pain

A report from the British Journal of Sports Medicine shows that commonly used drug store shoe inserts or customized orthotics are often ineffective in managing plantar heel pain.

Leflunomide May Sensitize the Insulin Receptor and Have an Anti-Glycemic Effect

An animal model study in the Journal of Endocrinololgy reports the potential use of leflunomide in the control of hyperglycemia in male mice. 

2017 Rheumatology Year in Review

This retrospective review is drawn from the authors collection of the most impactful publications, research and news that occurred in 2017.  In no particular order, here are my top rheumatology advances, news and research reports for calendar year 2017.

Oral Anticoagulation Effective Following Hip and Knee Replacement Surgery

Many protocols call for anticoagulation after total hip or total knee arthroplasty to prevent venous thromboembolism (proximal deep-vein thrombosis or pulmonary embolism), and some reports have suggested a role for aspiring or direct oral anticoagulants as preventative therapy. The NEJM has reported that oral anticoagulation with rivaroxaban (Xarelto) followed by aspirin to be effective prophylaxis.

Calcium and Vitamin D Do Not Increase Cardiac Events/Death

An analysis of the UK Biobank study found no link between calcium/vitamin D supplementation and incident cardiovascular events/deaths in a large prospective study of 475,255 men and women aged 40 to 69 years.

Results published in Journal of Bone and Mineral Research used registry data to identify coded incident hospital admissions for ischemic heart disease (IHD), myocardial infarction (MI), and subsequent death.